SCHEMBL23714847

SCHEMBL23714847

OC1(c2cccc(Br)c2)CC(OCc2ccccc2)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.43
OPRM1 P35372 2/20 0.43
OPRL1 P41146 2/20 0.43
DPP4 P27487 1/20 0.43
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
KDM1A O60341 3/20 0.38
RCOR1 Q9UKL0 2/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSK P43235 1/20 0.38
SLC6A4 P31645 2/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
IDO1 P14902 2/20 0.36
AGXT P21549 2/20 0.36
ADAM17 P78536 2/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20284995 0.85 OPRL1 (0.51) OPRM1OPRL1DPP4CARM1PRMT6
SCHEMBL29660836 0.85 OPRM1 (0.43) OPRM1OPRL1DPP4CARM1PRMT6
SCHEMBL23714851 0.84 MAOB (0.43) MAOBOPRM1OPRL1DPP4CARM1
SCHEMBL30999182 0.76 GAA (0.42) OPRM1OPRL1DPP4KDM1ARCOR1
SCHEMBL27142230 0.75 CTSL (0.38) MAOBOPRM1OPRL1DPP4KDM1A
SCHEMBL25317048 0.75 LMNA (0.50) MAOBSLC6A2SLC6A3ADAM17EPHX2
SCHEMBL23704935 0.75 MAOB (0.42) MAOBOPRM1OPRL1SLC6A4SLC6A2
SCHEMBL30116853 0.75 KDM1A (0.38) MAOBOPRM1OPRL1DPP4KDM1A
SCHEMBL24105723 0.75 KDM1A (0.38) MAOBOPRM1OPRL1DPP4KDM1A
SCHEMBL26775766 0.74 CTSL (0.49) OPRM1OPRL1DPP4CARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB MAOB 975/4885OPRM1 4702/4885OPRL1 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.